Total trials
1,421
Active
280
Phase 3
81
Total enrollment
1,450,669
Pipeline matrix
Showing 40 of 145 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | 9 | ||||
| HPV vaccine | — | — | — | — | — | 2 | |
| IV Lidocaine | — | — | — | — | — | 1 | |
| IV Saline | — | — | — | — | — | 1 | |
| Shingrix | — | — | — | — | — | 1 | |
| Doxepin 6 mg | — | — | — | — | — | 1 | |
| Ramelteon 8 mg | — | — | — | — | — | 1 | |
| WHO-recommended periodic presumptive treatment | — | — | — | — | — | 1 | |
| Doxycycline post-exposure prophylaxis | — | — | — | — | — | 1 | |
| Semaglutide Auto-Injector | — | — | — | — | — | 1 | |
| Cimetidine 200 MG | — | — | — | — | — | 1 | |
| Perflutren lipid | — | — | — | — | — | 1 | |
| Bupivacaine | — | — | — | — | 3 | ||
| Avelumab | — | — | — | — | — | 1 | |
| Pentoxifylline | — | — | — | — | — | 1 | |
| Tocopherol | — | — | — | — | — | 1 | |
| 5-fluorouracil | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide/5-fluorouracil mixture | — | — | — | — | — | 1 | |
| Xylitol Chewing gum | — | — | — | — | — | 1 | |
| Bexsero | — | — | — | — | — | 1 | |
| Lactoferrin + Lysozyme | — | — | — | — | — | 1 | |
| Prednisone | — | — | — | — | 15 | ||
| Doxorubicin | — | — | — | — | 11 | ||
| Etoposide | — | — | — | — | 16 | ||
| Rituximab | — | — | — | — | 16 | ||
| Cyclophosphamide | — | — | — | 20 | |||
| CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine | — | — | — | — | 5 | ||
| Vincristine | — | — | — | — | 5 | ||
| Abemaciclib | — | — | — | — | 4 | ||
| Carboplatin | — | — | — | — | 16 | ||
| sargramostim | — | — | — | — | 11 | ||
| Psilocybin | — | — | — | 5 | |||
| filgrastim | — | — | — | — | — | 13 | |
| Nivolumab | — | — | — | — | — | 6 | |
| Pegfilgrastim | — | — | — | — | 4 | ||
| Mosunetuzumab | — | — | — | — | — | 3 | |
| Polatuzumab Vedotin | — | — | — | — | 3 | ||
| Lutetium Lu 177 Vipivotide Tetraxetan | — | — | — | — | — | 2 | |
| Retifanlimab | — | — | — | — | — | 2 |
105 more active programs hidden
Next readouts
- 2021-10-01
- 2022-11-25
- 2024-08-13
- 2024-11-30
- 2024-12-30
- 2025-06-03
- 2025-06-30
- 2025-07
- 2025-07-01
- 2025-07-15
Top conditions
- Depression51
- HIV Infections39
- Cardiovascular Diseases30
- HIV29
- Heart Diseases25
- Chronic Pain25
- Multiple Sclerosis25
- Stage IV Breast Cancer21
Frequently asked questions about University of Washington
- How many clinical trials does University of Washington have on ClinicalTrials.gov?
- University of Washington is listed as the lead sponsor on 1,421 clinical trials in ClinicalTrials.gov, 280 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Washington's trials are in Phase 3?
- 81 of University of Washington's trials are in Phase 3, spread across 145 active drug programs.
- What therapeutic areas does University of Washington focus on?
- University of Washington's most-studied conditions on ClinicalTrials.gov are Depression, HIV Infections, Cardiovascular Diseases, HIV, Heart Diseases.
- When are University of Washington's next clinical trial readouts?
- University of Washington has 10 upcoming primary-completion readouts tracked here; the soonest is “Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy”, expected around 2021-10-01.